In 2005, Crowther et al. presented a large randomized clinical trial finding that targeted treatment of GDM (including insulin), as opposed to routine care at the time, reduced composite serious perinatal complications (defined as defined as death, shoulder dystocia, bone fracture, and nerve palsy) from 4 percent to 1 percent [37]. This evidence concerns the gene INS and gestational diabetes.